PT1268799E - Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular - Google Patents

Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular Download PDF

Info

Publication number
PT1268799E
PT1268799E PT01922997T PT01922997T PT1268799E PT 1268799 E PT1268799 E PT 1268799E PT 01922997 T PT01922997 T PT 01922997T PT 01922997 T PT01922997 T PT 01922997T PT 1268799 E PT1268799 E PT 1268799E
Authority
PT
Portugal
Prior art keywords
cadherin
human
antibody
adverse effects
vascular permeability
Prior art date
Application number
PT01922997T
Other languages
English (en)
Portuguese (pt)
Inventor
Fang Liao
Daniel J Hicklin
Peter Bohlen
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PT1268799E publication Critical patent/PT1268799E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01922997T 2000-03-31 2001-03-30 Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular PT1268799E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31

Publications (1)

Publication Number Publication Date
PT1268799E true PT1268799E (pt) 2009-05-11

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01922997T PT1268799E (pt) 2000-03-31 2001-03-30 Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular

Country Status (12)

Country Link
US (4) US7371574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1268799B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003529370A (cg-RX-API-DMAC7.html)
AT (1) ATE425255T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001249737A1 (cg-RX-API-DMAC7.html)
CA (1) CA2404576A1 (cg-RX-API-DMAC7.html)
CY (1) CY1109097T1 (cg-RX-API-DMAC7.html)
DE (1) DE60137915D1 (cg-RX-API-DMAC7.html)
DK (1) DK1268799T3 (cg-RX-API-DMAC7.html)
ES (1) ES2323938T3 (cg-RX-API-DMAC7.html)
PT (1) PT1268799E (cg-RX-API-DMAC7.html)
WO (1) WO2001075109A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
EP1560850A2 (en) * 2002-11-14 2005-08-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (ja) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd 癌転移抑制剤
US20040167076A1 (en) * 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JPH07500019A (ja) * 1992-04-17 1995-01-05 ドーニー　アイ　インスティテュート カドヘリン物質および方法
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
CA2327530A1 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
US20080311121A1 (en) 2008-12-18
US20090060909A1 (en) 2009-03-05
DE60137915D1 (de) 2009-04-23
JP2003529370A (ja) 2003-10-07
EP1268799A2 (en) 2003-01-02
WO2001075109A2 (en) 2001-10-11
ES2323938T3 (es) 2009-07-28
CA2404576A1 (en) 2001-10-11
US20020160003A1 (en) 2002-10-31
ATE425255T1 (de) 2009-03-15
US20080317750A1 (en) 2008-12-25
CY1109097T1 (el) 2014-07-02
AU2001249737A1 (en) 2001-10-15
EP1268799B1 (en) 2009-03-11
US7371574B2 (en) 2008-05-13
DK1268799T3 (da) 2009-07-06
WO2001075109A3 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
CY1109097T1 (el) Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
EP0344940A3 (en) Antibodies to human papillomavirus latent proteins, diagnostic systems and methods
DE69230545D1 (de) Antikörperderivate
IL138497A0 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
PT807124E (pt) Anticorpo monoclonal contra o receptor tirosina-quinase flt4 e sua utilizacao em diagnostico e terapeutica
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
DE69222303D1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
DK130791D0 (da) Monoklonale antistoffer, isaer for hb alc.
EP1285577A4 (en) CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF
DK0946873T3 (da) Fremgangsmåde til diagnose af allergisk bronkopulmonal aspergillose
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
ATE429449T1 (de) Anti-fas-ligand antikörper und testmethode unter verwendung derselben
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
NO930705L (no) Fremgangsmaate for bestemmelse av en vannbehandlingspolymer i en vandig proeve
EP0522169A4 (en) Antihuman stromelysin monoclonal antibody and diagnosis of rheumatoid arthritis by enzyme immunoassay
DE69529744D1 (de) Monoklonale antikörper spezifisch gegen vaskuläres endothelzellartigen endoglyx-1, das antigen selbst und seine verwendungen
IL129236A0 (en) Monoclonal antibodies against a human act and serine protease complex
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
DE3785175D1 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
DK414386D0 (da) Monoklonalt antistof, cellelinje til fremstilling deraf og antistoffets anvendelse
WO2001033400A8 (en) Automated methods for creation of adaptive trade specifications
DK98692A (da) Monoklonalt antistof og fremgangsmaade til fremstilling deraf, hybridoma, som producerer det monoklonale antistof, og proeve for tumorcellefoelsomhed under anvendelse af det monoklonale antistof
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.